Clear skies. Low near 40F. Winds E at 10 to 15 mph..
Clear skies. Low near 40F. Winds E at 10 to 15 mph.
<\/i> Updated: April 2, 2022 @ 3:39 pm<\/small><\/p>\n
Health care stocks may not be the most exciting segment in the stock market<\/a>. But they came to the fore over the past two years amid the pandemic. but it is often relatable among consumers. Far too often, people take health care for granted and the global pandemic served as a reminder of the importance of the companies in this sector. What\u2019s more, with market sentiments under pressure from rising interest rates and the ongoing war in Ukraine, some are rotating into more defensive stocks such as health care stocks<\/a>. After all, medicines and health care services will still be in need regardless of the state of the economy.
On top of that, the health care industry also rarely lacks new developments. Earlier this week, IGM Biosciences<\/strong> (NASDAQ: IGMS<\/a>) announced that it has entered into an exclusive partnership with Sanofi<\/strong> (NASDAQ: SNY<\/a>). The collaboration is to create and commercialize new therapies for oncology, immunology, and inflammation indications. As a result, IGMS stock has soared by more than 65% within the past week.\u00a0
Besides that, Moderna<\/strong> (NASDAQ: MRNA<\/a>) also recently announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its amendment to the emergency use authorization for a second booster dose of its coronavirus vaccine. As such, MRNA stock has climbed by approximately 15% over the past month. Considering all these, let\u2019s take a look at some of the top health care stocks<\/a> in the stock market today.\u00a0
Axsome Therapeutics<\/strong> is a biopharmaceutical company that engages in the development of therapies for the management of central nervous system (CNS) disorders. Its core CNS portfolio includes five product candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. Investors who followed the company closely would know that Axsome has made significant strides over the past year. AXSM stock has risen more than 30% over the past month.\u00a0
In March, Axsome announced its fourth-quarter and full-year 2021 financials. The company claims that the FDA\u2019s review of its non-disclosure agreement for AXS-05 in depression is progressing. Well, this suggests that the drug may receive approval soon. Besides that, Axsome saw a year of continuous progress in 2021 as it continues to advance the rest of its late-stage CNS pipelines. This includes the AXS-14 for fibromyalgia and Phase 3 trials of AXS-12 in narcolepsy and AXS-05 in Alzheimer\u2019s disease agitation.\u00a0\u00a0
Now, Axsome is not resting on its laurels. Earlier this week, the company announced that it has entered into a definitive agreement to acquire Sunosi (solriamfetol) from Jazz Pharmaceuticals<\/strong> (NASDAQ: JAZZ<\/a>). The drug is a dual-acting dopamine and norepinephrine reuptake inhibitor to improve wakefulness in adults with excessive daytime sleepiness. It is usually indicated for patients who have narcolepsy or obstructive sleep apnea. Safe to say, the acquisition will strengthen Axsome\u2019s industry-leading neuroscience portfolio. Given these exciting developments, would you consider adding AXSM stock to your watchlist?
[Read More]<\/strong>\u00a0Stock Market Today: Dow Jones, S&P 500 Rebounds; GameStop (GME) Seeks Stock Split Amid Renewed Meme Stocks Hype<\/a>
Following that, we will be looking at another health care giant, Johnson & Johnson (JNJ)<\/strong>. In detail, the company engages in the research and development, manufacture, and sale of a range of products for the health care industry. This includes day-to-day products such as over-the-counter medicines, oral care, women\u2019s health, and baby care. Additionally, the company also has a Pharmaceutical segment that focuses on delivering new transformational medicines for unmet medical needs worldwide.
Recently, JNJ announced that the U.S. FDA has approved CABENUVA for the treatment of HIV-1 in virologically suppressed adolescents who are 12 years of age or older. The drug contains ViiV Healthcare\u2019s cabotegravir extended-release injectable suspension and JNJ\u2019s rilpivirine extended-release injectable suspension in a single-dose vial. As a result, this marks the first and only complete long-acting HIV-1 treatment regimen for eligible adolescents. This is an important milestone for JNJ as it continues to improve the HIV treatment options for people affected with HIV.\u00a0
Keen investors should also note that JNJ will be announcing its fiscal 2022 first-quarter financial results on April 19, 2022. So, let us have a look at how the company fared over the past year. In 2021, the company reported full-year sales of $93.8 billion, reflecting an increase of 13.6% year-over-year. Meanwhile, its full-year earnings per share were $7.81, up by 41.7% year-over-year. All in all, fiscal 2021 was a strong year for the company that reflects continued strength across all segments of its business. Considering these factors, would you buy JNJ stock ahead of its earnings report?
[Read More]<\/strong>\u00a0Top Stock Market News For Today April 1, 2022<\/a>
To sum up the list, we have the German-based clinical-stage biotech company, BioNTech<\/strong>. The company made its name as one of the pioneers that developed the coronavirus vaccine with Pfizer<\/strong> (NYSE: PFE<\/a>). Aside from that, it also develops a broad product pipeline using different scientific approaches and technology platforms. Despite losing a quarter of its value this year, BNTX stock has still risen by nearly 50% over the past year.
On Wednesday, BioNTech announced its fourth-quarter and full-year 2021 earnings report. The company\u2019s total revenues for the quarter increased to $6.08 billion, compared to a mere $381.5 million in the prior year\u2019s quarter. Meanwhile, the company posted a net profit of $3.49 billion, representing a staggering increase of 761% year-over-year. Overall, the year 2021 was an exceptional year for the company as it made momentous impacts on human health and the global economy. This would serve as a building block for the company to continue its momentum this year.\u00a0
Two years into the pandemic, it seems that there is still a need for the coronavirus vaccine. Hence, the company has expanded an ongoing clinical trial program to develop new vaccines and patterns of administration for better protection against the Omicron variant. The number of participants will be increased to 2,150 from the 1,420 announced in January. This would hopefully allow the company to better understand the protection these vaccines provide against the latest variant and provide cross-protection against previous variants. All things considered, should investors be keeping a close tab on BNTX stock moving forward?\u00a0
If you enjoyed this article and you\u2019re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!<\/a>
This article originally ran on stockmarket.com<\/a>.
Your comment has been submitted.<\/p>\n